@article{30e69e46fe0242408f61d2914a158e1c,
title = "Acute Responses to Diuretic Therapy in Extremely Low Gestational Age Newborns: Results from the Prematurity and Respiratory Outcomes Program Cohort Study",
abstract = "Objective: To determine if daily respiratory status improved more in extremely low gestational age (GA) premature infants after diuretic exposure compared with those not exposed in modern neonatal intensive care units. Study design: The Prematurity and Respiratory Outcomes Program (PROP) was a multicenter observational cohort study of 835 extremely premature infants, GAs of 230/7-286/7 weeks, enrolled in the first week of life from 13 US tertiary neonatal intensive care units. We analyzed the PROP study daily medication and respiratory support records of infants ≤34 weeks postmenstrual age. We determined whether there was a temporal association between the administration of diuretics and an acute change in respiratory status in premature infants in the neonatal intensive care unit, using an ordered categorical ranking of respiratory status. Results: Infants in the diuretic exposed group of PROP were of lower mean GA and lower mean birth weight (P <.0001). Compared with infants unexposed to diuretics, the probability (adjusted for infant characteristics including GA, birth weight, sex, and respiratory status before receiving diuretics) that the exposed infants were on a higher level of respiratory support was significantly greater (OR, >1) for each day after the initial day of diuretic exposure. Conclusions: Our analysis did not support the ability of diuretics to substantially improve the extremely premature infant's respiratory status. Further study of both safety and efficacy of diuretics in this setting are warranted. Trial Registration: Clinicaltrials.gov: NCT01435187.",
keywords = "diuretic, prematurity, respiratory distress",
author = "{Prematurity and Respiratory Outcomes Program} and Blaisdell, {Carol J.} and James Troendle and Anne Zajicek and Claire Chougnet and Greenberg, {James M.} and William Hardie and Jobe, {Alan H.} and Karen McDowell and Thomas Ferkol and Holland, {Mark R.} and James Kemp and Levy, {Philip T.} and Phillip Tarr and Singh, {Gautam K.} and Barbara Warner and Aaron Hamvas and Ballard, {Philip L.} and Ballard, {Roberta A.} and Keller, {Roberta L.} and Khan, {Amir M.} and Leslie Lusk and Nielson, {Dennis W.} and Rogers, {Elizabeth E.} and Durand, {David J.} and Merrill, {Jeffrey D.} and Eichenwald, {Eric C.} and Candice Fike and Tina Hartert and Paul Moore and Judy Aschner and Scott Guthrie and Nathalie Maitre and Marshall Summar and Carl D'Angio and Vasanth Kumar and Tom Mariani and Gloria Pryhuber and Reynolds, {Anne Marie} and Kristin Scheible and Timothy Stevens and Clement Ren and Ryan, {Rita M.} and Cotten, {C. Michael} and Kim Fisher and Jack Sharp and Voynow, {Judith A.} and Stephanie Davis and Brenda Poindexter and Jonas Ellenberg and Rui Feng",
note = "Funding Information: Supported by the National Institutes of Health grant numbers U01 HL101794 , U01 HL101456 , U01 HL101798 , U01 HL101813 , U01 HL101465 , U01 HL101800 , and 5RO1 HL105702 from the National Heart, Lung, and Blood Institute and support from the Eunice Kennedy Shriver National Institute of Child Health and Human Development under the Best Pharmaceuticals for Children Act to U01 HL101794 . C.B., J.T., and A.Z. are employees of the National Institutes of Health (NIH) and have no competing financial interests nor other conflicts of interest. The NIH, as an employment agency, had no role in (1) the study design; (2) the collection, analysis, and interpretation of data; (3) the writing of the report; and (4) the decision to submit the paper for publication. The authors declare no conflicts of interest. Publisher Copyright: {\textcopyright} 2018",
year = "2018",
month = jun,
doi = "10.1016/j.jpeds.2018.01.066",
language = "English",
volume = "197",
pages = "42--47.e1",
journal = "Journal of Pediatrics",
issn = "0022-3476",
}